Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 848
- Registration Number
- NCT00337727
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00314743
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00293384
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00248547
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-05-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 492
- Registration Number
- NCT00169572
- Locations
- 🇨🇳
GSK Investigational Site, Tao Yuan County, Taiwan
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
- Conditions
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00080444
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
- Conditions
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00048607
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
- Conditions
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 800
- Registration Number
- NCT00048594
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00035048
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 900
- Registration Number
- NCT00034983
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.